§7329 — Title 38 Veterans' Benefits | U.S. Code

Summary

The Secretary must set up at least six Veterans Health Administration centers for Parkinson’s Disease research, education, and clinical care. The Secretary must pick locations so they are spread out across the country. Centers that were running on January 1, 2005 should be kept unless they fail to meet standards or do not show they can do the work well now or soon. Each chosen site must be judged by a peer review panel to have top scientific and clinical merit. Centers must have, or be able to develop, key things: a link with an accredited medical school that trains neurologists, the ability to attract creative researchers, an advisory committee that includes veterans, ways to evaluate the center’s work, the ability to coordinate nationally with other centers, a plan to form a consortium to bring care to facilities without centers, and a way to build a national data collection on care for neurodegenerative diseases. The Under Secretary for Health must create the expert panel to review proposals. Panel members are experts in neurodegenerative diseases, serve no longer than two years (but the first appointees are split so half serve three years and half serve two years), and the panel is not covered by chapter 10 of title 5. Centers will be created and run only if money is provided by Congress. Before funding new sites beyond the 2005 centers, the Secretary must make sure those 2005 centers have enough funding to work well. Congress may appropriate whatever sums are needed, and the Under Secretary may allocate funds from the Department medical services account and the medical and prosthetics research account. Research at the centers can compete for money from the medical and prosthetics research account and gets priority when funds are for Parkinson’s disease and other movement disorders.

Title 38, §7329

Veterans' Benefits — Source: USLM XML via OLRC

(a)(1)The Secretary, upon the recommendation of the Under Secretary for Health, shall designate not less than six Department health-care facilities as the locations for centers of Parkinson’s Disease research, education, and clinical activities.

(2)Subject to the availability of appropriations for such purpose, the Secretary shall establish and operate centers of Parkinson’s Disease research, education, and clinical activities centers at the locations designated pursuant to paragraph (1).

(b)(1)In designating Department health-care facilities for centers under subsection (a), the Secretary, upon the recommendation of the Under Secretary for Health, shall assure appropriate geographic distribution of such facilities.

(2)Except as provided in paragraph (3), the Secretary shall designate as the location for a center of Parkinson’s Disease research, education, and clinical activities pursuant to subsection (a)(1) each Department health-care facility that as of January 1, 2005, was operating a Parkinson’s Disease research, education, and clinical center.

(3)The Secretary may not under subsection (a) designate a facility described in paragraph (2) if (on the recommendation of the Under Secretary for Health) the Secretary determines that such facility—

(A)does not meet the requirements of subsection (c); or

(B)has not demonstrated—

(i)effectiveness in carrying out the established purposes of such center; or

(ii)the potential to carry out such purposes effectively in the reasonably foreseeable future.

(c)(1)The Secretary may not designate a Department health-care facility as a location for a center under subsection (a) unless the peer review panel established under subsection (d) has determined under that subsection that the proposal submitted by such facility as a location for a new center under subsection (a) is among those proposals that meet the highest competitive standards of scientific and clinical merit.

(2)The Secretary may not designate a Department health-care facility as a location for a center under subsection (a) unless the Secretary (upon the recommendation of the Under Secretary for Health) determines that the facility has (or may reasonably be anticipated to develop) each of the following:

(A)An arrangement with an accredited medical school that provides education and training in neurology and with which the Department health-care facility is affiliated under which residents receive education and training in innovative diagnosis and treatment of chronic neurodegenerative diseases and movement disorders, including Parkinson’s Disease.

(B)The ability to attract the participation of scientists who are capable of ingenuity and creativity in health-care research efforts.

(C)An advisory committee composed of veterans and appropriate health-care and research representatives of the Department health-care facility and of the affiliated school or schools to advise the directors of such facility and such center on policy matters pertaining to the activities of the center during the period of the operation of such center.

(D)The capability to conduct effectively evaluations of the activities of such center.

(E)The capability to coordinate (as part of an integrated national system) education, clinical, and research activities within all facilities with such centers.

(F)The capability to jointly develop a consortium of providers with interest in treating neurodegenerative diseases, including Parkinson’s Disease and other movement disorders, at facilities without centers established under subsection (a) in order to ensure better access to state-of-the-art diagnosis, care, and education for neurodegenerative disorders throughout the health-care system of the Department.

(G)The capability to develop a national repository in the health-care system of the Department for the collection of data on health services delivered to veterans seeking care for neurodegenerative diseases, including Parkinson’s Disease, and other movement disorders.

(d)(1)The Under Secretary for Health shall establish a panel to assess the scientific and clinical merit of proposals that are submitted to the Secretary for the establishment of centers under this section.

(2)(A)The membership of the panel shall consist of experts in neurodegenerative diseases, including Parkinson’s Disease and other movement disorders.

(B)Members of the panel shall serve for a period of no longer than two years, except as specified in subparagraph (C).

(C)Of the members first appointed to the panel, one half shall be appointed for a period of three years and one half shall be appointed for a period of two years, as designated by the Under Secretary at the time of appointment.

(3)The panel shall review each proposal submitted to the panel by the Under Secretary and shall submit its views on the relative scientific and clinical merit of each such proposal to the Under Secretary.

(4)The panel shall not be subject to chapter 10 of title 5.

(e)Before providing funds for the operation of a center designated under subsection (a) at a Department health-care facility other than at a facility designated pursuant to subsection (b)(2), the Secretary shall ensure that each Parkinson’s Disease center at a facility designated pursuant to subsection (b)(2) is receiving adequate funding to enable that center to function effectively in the areas of Parkinson’s Disease research, education, and clinical activities.

(f)There are authorized to be appropriated such sums as may be necessary for the support of the research and education activities of the centers established pursuant to subsection (a). The Under Secretary for Health shall allocate to such centers from other funds appropriated generally for the Department medical services account and medical and prosthetics research account, as appropriate, such amounts as the Under Secretary for Health determines appropriate.

(g)Activities of clinical and scientific investigation at each center established under subsection (a) shall be eligible to compete for the award of funding from funds appropriated for the Department medical and prosthetics research account. Such activities shall receive priority in the award of funding from such account insofar as funds are awarded to projects for research in Parkinson’s Disease and other movement disorders.

Notes & Related Subsidiaries

Editorial Notes

Codification A substantially identical section enacted by Pub. L. 109–444, § 6(a)(1), Dec. 21, 2006, 120 Stat. 3308, was repealed by Pub. L. 109–461, title X, § 1006(b), Dec. 22, 2006, 120 Stat. 3468, set out as a Coordination of Provisions With Pub. L. 109–444 note under section 101 of this title.

Amendments

2022—Subsec. (d)(4). Pub. L. 117–286 substituted “chapter 10 of title 5.” for “the Federal Advisory Committee Act.”

Statutory Notes and Related Subsidiaries

Effective Date

Pub. L. 109–461, title II, § 209(b), Dec. 22, 2006, 120 Stat. 3418, provided that: “section 7329 and 7330 of title 38, United States Code, as added by subsection (a), shall take effect at the end of the 30-day period beginning on the date of the enactment of this Act [Dec. 22, 2006].” Pub. L. 109–444, § 6(b), Dec. 21, 2006, 120 Stat. 3312, which provided that this section and section 7330 of this title would take effect at the end of the 30-day period beginning on Dec. 21, 2006, was repealed by Pub. L. 109–461, title X, § 1006(b), Dec. 22, 2006, 120 Stat. 3468, set out as a Coordination of Provisions With Pub. L. 109–444 note under section 101 of this title.

§7329 Parkinson’s Disease Research, Education, and Clinical Centers